Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1701861

registered interest
date	17/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antimicrobials: Drug Resistance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when she plans to publish the next action plan for antimicrobial resistance.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	22343
answer	answer is ministerial correction date of answer 23/04/2024 answer text <p>In 2019, the Government published the first of four five-year national action plans (NAP), aimed at tackling antimicrobial resistance (AMR) within and beyond our own borders. This plan is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/uk-5-year-action-plan-for-antimicrobial-resistance-2019-to-2024" target="_blank">https://www.gov.uk/government/publications/uk-5-year-action-plan-for-antimicrobial-resistance-2019-to-2024</a></p><p>We are now in the process of developing the second five-year NAP, which will run from 2024 to 2029. It will be designed to ensure progress is maintained towards delivering our 20-year vision on AMR, in which resistance is effectively contained and controlled by 2040. Further information on the 20-year vision is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/uk-20-year-vision-for-antimicrobial-resistance" target="_blank">https://www.gov.uk/government/publications/uk-20-year-vision-for-antimicrobial-resistance</a></p><p>The 2024 to 2029 AMR NAP is being co-developed across the Government, its agencies, and the administrations in Scotland, Wales, and Northern Ireland, with support from a wide range of external stakeholders, and informed by the responses to the Call for Evidence. The NAP is expected to be published in 2024.</p><p>The 2024 to 2029 AMR NAP will build on the achievements of the 2019 to 2024 NAP, whilst recognising where there is more to do, and will be aligned with global plans and frameworks for action.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 23/04/2024 12:31:44 answering member 4492 label Biography information for Maria Caulfield
tabling member	4488 label Biography information for Martyn Day

1701128

registered interest
date	15/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antibiotics: Drug Resistance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Answer of 14 March 2022 to Question 133232 on Antibiotics: Drug Resistance and to the policy paper entitled UK five-year action plan for antimicrobial resistance: 2019 to 2024, published on 24 January 2019, what recent progress her Department has made on halving healthcare-associated Gram-negative blood stream infections.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	21728
answer	answer is ministerial correction date of answer 23/04/2024 answer text <p>As described in the answer of 14 March 2022 to Question 133232, progress towards the target of halving healthcare-associated Gram-negative bloodstream infections (GNBSI) has proved very challenging, in part due to the diverse nature of the underlying causes of these infections. Data on the incidence of these infections in England is published quarterly by the UK Health Security Agency, and is available at the following link:</p><p><br> <a href="https://www.gov.uk/government/statistics/mrsa-mssa-gram-negative-bacteraemia-and-cdi-quarterly-report/quarterly-epidemiological-commentary-mandatory-gram-negative-bacteraemia-mrsa-mssa-and-c-difficile-infections-data-up-to-october-to-december-2023#epidemiological-analyses-of-gram-negative-bacteraemia-data" target="_blank">https://www.gov.uk/government/statistics/mrsa-mssa-gram-negative-bacteraemia-and-cdi-quarterly-report/quarterly-epidemiological-commentary-mandatory-gram-negative-bacteraemia-mrsa-mssa-and-c-difficile-infections-data-up-to-october-to-december-2023#epidemiological-analyses-of-gram-negative-bacteraemia-data</a></p><p><br> Incidence of the three main healthcare-associated GNBSI organisms, E. coli, klebsiella pneumoniae, and pseudomonas aeruginosa, has fluctuated between 2019 and 2024, including a sharp decline in the incidence of E. coli seen during the COVID-19 pandemic. However, overall, the total incidence of healthcare associated GNBSI remains significantly above the target.</p><p>We are currently developing the 2024 to 2029 antimicrobial resistance national action plan. We anticipate that in the delivery of this plan, we will continue to focus on GNBSI, building on lessons learnt over the past five years.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 23/04/2024 15:47:27 answering member 4492 label Biography information for Maria Caulfield
tabling member	4488 label Biography information for Martyn Day